Successful cardiac transplantation after 4 cases of DeBakey left ventricular assist device failure

Christiansen, Stefan; Aken, Hugo Van; Breithardt, G.; Scheld, H. H.; Hammel, Dieter

doi:10.1016/s1053-2498(01)00382-5

Cited by 17 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These devices may be technically easier to implant, are suitable for smaller patients, and have been shown to safely bridge patients to cardiac transplantation. 10,11 However, controversy remains Table 3). about the effects of the low-pulsatile blood flow produced by these devices on end-organ function.…”

Section: Discussionmentioning

confidence: 99%

Renal Function After Implantation of Continuous Versus Pulsatile Flow Left Ventricular Assist Devices

Sandner

Zimpfer

Zrunek

et al. 2008

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Renal Function After Implantation of Continuous Versus Pulsatile Flow Left Ventricular Assist Devices

Sandner

Zimpfer

Zrunek

et al. 2008

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Depending on the available publications, the thromboembolic events occur with a frequency of 2.7 to 48.8% 37 . The most serious events are usually cerebral infarctions with persistent neurological deficits because nearly all of these patients do not survive to transplantation 4 .…”

Section: Complicationsmentioning

confidence: 99%

“…The most serious events are usually cerebral infarctions with persistent neurological deficits because nearly all of these patients do not survive to transplantation 4 . The great differences in the reported frequency of the thromboembolic events can be explained by different LVAD types, various anticoagulation protocols, different duration of LVAD support, distinct patient selection criteria, and the difficulty to define thromboembolism 37 . Furthermore, the occurrence of thromboembolic complications is influenced by numerous factors, for example, age of the patient, the patient's preoperative status, the duration of extracorporeal circulation for LVAD implantation, the transfusion requirements, the altered rheologic conditions and different velocities of blood flow, the number and activation status of the blood cells, septic complications, the anticoagulation management, and the device design 37,38 .…”

Section: Complicationsmentioning

confidence: 99%

Past, Present, and Future of Long‐Term Mechanical Cardiac Support in Adults

Christiansen

Klocke

Autschbach

2008

Journal of Cardiac Surgery

Self Cite

View full text Add to dashboard Cite

The growing number of heart failure patients and the scarcity of donor organs give rise to the development of mechanical circulatory support devices for a long-term support. After approximately 15 years of experience, these devices should be critically evaluated. The presented article gives an overview on the currently most often used mechanical circulatory support systems, describes the indications for implantation (bridge to cardiac transplantation, destination therapy, and bridge to recovery), the complications like bleeding, thromboembolic events, infections, and technical failures, and analyzes the costs of this therapy. Furthermore, alternative treatment options like cardiac transplantation, coronary artery bypass grafting, cardiac valve surgery, defibrillator implantation, multisite pacing, dynamic and passive cardiomyoplasty, partial left ventriculectomy (PLV), Myosplint implantation (Myocor, Maple Grove, MN, USA), stem cell therapy, and xenotransplantation are shortly presented, and the future of mechanical support devices is discussed. Despite a great number of patients benefitting from mechanical support devices, the treatment with these devices will only compete with other therapeutic strategies if the rates of complications and technical failures as well as the costs are significantly reduced. Furthermore, innovative therapies like biochemical influencing of the cardiac metabolism have a high potential and may play an important role in the future.

show abstract

“…But if these patients cannot be bridged to recovery, they must be supported for years until the neoplastic disease is cured to undergo cardiac transplantation. During this time they have a great risk of infectious, thromboembolic and bleeding complications as well as technical failures [48,[50][51][52][53]. A different alternative in these patients may be the implantation of assist devices as destination therapy [54][55][56] which would help to avoid the dilemma of cardiac transplantation in tumor patients.…”

Section: Clinical Surgical Proceduresmentioning

confidence: 99%

Doxorubicin in experimental and clinical heart failure

Christiansen

Autschbach

2006

European Journal of Cardio-Thoracic Surgery

Self Cite

View full text Add to dashboard Cite

Doxorubicin-induced heart failure is a rare but serious illness due to the well-known treatment difficulties. Prevention strategies have not demonstrated the expected success and unfortunately, this specific type of heart failure does not respond to the usual medical therapy as other kinds of heart failure. Therefore, surgical procedures may be necessary in some patients. Cardiac transplantation is performed in most cases but it requires the cure of the neoplastic disease. This usually requires a recurrence-free interval of several years which is associated with a high attrition rate in these patients due to their cardiac disease. Therefore, other conservative and surgical treatment concepts were developed during the last years. This review presents the most common procedures and discusses their efficacy as well as their clinical applicability.

show abstract

Successful cardiac transplantation after 4 cases of DeBakey left ventricular assist device failure

Cited by 17 publications

References 9 publications

Renal Function After Implantation of Continuous Versus Pulsatile Flow Left Ventricular Assist Devices

Renal Function After Implantation of Continuous Versus Pulsatile Flow Left Ventricular Assist Devices

Past, Present, and Future of Long‐Term Mechanical Cardiac Support in Adults

Doxorubicin in experimental and clinical heart failure

Contact Info

Product

Resources

About